InvestorsHub Logo
Followers 75
Posts 9162
Boards Moderated 0
Alias Born 04/25/2002

Re: None

Thursday, 02/02/2023 11:24:52 AM

Thursday, February 02, 2023 11:24:52 AM

Post# of 44690
As part of the FDA's Coronavirus Treatment Acceleration Program, Relief Therapeutics, a Swiss company, is examining the effectiveness of Aviptadil, a patented synthetic version of a human vasoactive intestinal polypeptide (VIP), for COVID-19-related ARDS at New York University Langone (NYU Langone Health) (CTAP).

Do a find on : "Relief"
https://www.bloomberg.com/press-releases/2023-01-31/at-7-5-cagr-global-peptide-synthesis-market-size-share-to-surpass-us-845-68-million-by-2028-peptide-synthesis-industry